What is the current market valuation of the US chronic granulomatous-disease market?

The market valuation was $0.269 Million in 2024. Read More

What is the projected market valuation for the US chronic granulomatous-disease market in 2035?

The projected valuation for 2035 is $0.57 Million. Read More

What is the expected CAGR for the US chronic granulomatous-disease market during the forecast period 2025 - 2035?

The expected CAGR is 7.05% during the forecast period. Read More

Which companies are the key players in the US chronic granulomatous-disease market?

Key players include Novartis, Bristol-Myers Squibb, Amgen, Roche, GSK, Sanofi, Pfizer, and Merck & Co. Read More

What are the market segments for the US chronic granulomatous-disease market?

Segments include Type, Diagnosis, Treatment, and End-User. Read More

What was the valuation for X-Linked Chronic Granulomatous Disease in 2024?

The valuation for X-Linked Chronic Granulomatous Disease was $0.161 Million in 2024. Read More

What is the projected valuation for Autosomal Recessive Chronic Granulomatous Disease in 2035?

The projected valuation for Autosomal Recessive Chronic Granulomatous Disease in 2035 is $0.23 Million. Read More

Which diagnostic methods are included in the US chronic granulomatous-disease market?

Diagnostic methods include Neutrophil Function Tests, Genetic Testing, Prenatal Testing, and others. Read More

What was the valuation for Infection Management treatment in 2024?

The valuation for Infection Management treatment was $0.1 Million in 2024. Read More

What is the projected valuation for hospitals as an end-user in 2035?

The projected valuation for hospitals as an end-user in 2035 is $0.23 Million. Read More

US Chronic Granulomatous Disease Market

ID: MRFR/Pharma/18354-HCR

100 Pages

Satyendra Maurya

Last Updated: April 06, 2026

US Chronic Granulomatous Disease Market Research Report By Diagnosis (Neutrophil Function Tests, Genetic Testing, Others), By Treatment (Infection Management, Interferon-gamma, Stem Cell Transplantation) and By End-User (Hospitals, Others) - Growth & Industry Forecast 2025 To 2035

US Chronic Granulomatous Disease Market Infographic

Summary Table of Contents Segmentation Download PDF

Certified Researchers

Customize Report

1 SECTION I: EXECUTIVE SUMMARY AND KEY HIGHLIGHTS
1. 1.1 EXECUTIVE SUMMARY
  1. 1.1.1 Market Overview
  2. 1.1.2 Key Findings
  3. 1.1.3 Market Segmentation
  4. 1.1.4 Competitive Landscape
  5. 1.1.5 Challenges and Opportunities
  6. 1.1.6 Future Outlook
2 SECTION II: SCOPING, METHODOLOGY AND MARKET STRUCTURE
1. 2.1 MARKET INTRODUCTION
  1. 2.1.1 Definition
  2. 2.1.2 Scope of the study
    1. 2.1.2.1 Research Objective
    2. 2.1.2.2 Assumption
    3. 2.1.2.3 Limitations
2. 2.2 RESEARCH METHODOLOGY
  1. 2.2.1 Overview
  2. 2.2.2 Data Mining
  3. 2.2.3 Secondary Research
  4. 2.2.4 Primary Research
    1. 2.2.4.1 Primary Interviews and Information Gathering Process
    2. 2.2.4.2 Breakdown of Primary Respondents
  5. 2.2.5 Forecasting Model
  6. 2.2.6 Market Size Estimation
    1. 2.2.6.1 Bottom-Up Approach
    2. 2.2.6.2 Top-Down Approach
  7. 2.2.7 Data Triangulation
  8. 2.2.8 Validation
3 SECTION III: QUALITATIVE ANALYSIS
1. 3.1 MARKET DYNAMICS
  1. 3.1.1 Overview
  2. 3.1.2 Drivers
  3. 3.1.3 Restraints
  4. 3.1.4 Opportunities
2. 3.2 MARKET FACTOR ANALYSIS
  1. 3.2.1 Value chain Analysis
  2. 3.2.2 Porter's Five Forces Analysis
    1. 3.2.2.1 Bargaining Power of Suppliers
    2. 3.2.2.2 Bargaining Power of Buyers
    3. 3.2.2.3 Threat of New Entrants
    4. 3.2.2.4 Threat of Substitutes
    5. 3.2.2.5 Intensity of Rivalry
  3. 3.2.3 COVID-19 Impact Analysis
    1. 3.2.3.1 Market Impact Analysis
    2. 3.2.3.2 Regional Impact
    3. 3.2.3.3 Opportunity and Threat Analysis
4 SECTION IV: QUANTITATIVE ANALYSIS
1. 4.1 Medical Device, BY Type (USD Million)
  1. 4.1.1 X-Linked Chronic Granulomatous Disease
  2. 4.1.2 Autosomal Recessive Chronic Granulomatous Disease
2. 4.2 Medical Device, BY Diagnosis (USD Million)
  1. 4.2.1 Neutrophil Function Tests
  2. 4.2.2 Genetic Testing
  3. 4.2.3 Prenatal Testing
  4. 4.2.4 Others
3. 4.3 Medical Device, BY Treatment (USD Million)
  1. 4.3.1 Infection Management
  2. 4.3.2 Interferon-gamma
  3. 4.3.3 Stem Cell Transplantation
  4. 4.3.4 Others
4. 4.4 Medical Device, BY End-User (USD Million)
  1. 4.4.1 Hospitals
  2. 4.4.2 Clinical Laboratories
  3. 4.4.3 Others
5 SECTION V: COMPETITIVE ANALYSIS
1. 5.1 Competitive Landscape
  1. 5.1.1 Overview
  2. 5.1.2 Competitive Analysis
  3. 5.1.3 Market share Analysis
  4. 5.1.4 Major Growth Strategy in the Medical Device
  5. 5.1.5 Competitive Benchmarking
  6. 5.1.6 Leading Players in Terms of Number of Developments in the Medical Device
  7. 5.1.7 Key developments and growth strategies
    1. 5.1.7.1 New Product Launch/Service Deployment
    2. 5.1.7.2 Merger & Acquisitions
    3. 5.1.7.3 Joint Ventures
  8. 5.1.8 Major Players Financial Matrix
    1. 5.1.8.1 Sales and Operating Income
    2. 5.1.8.2 Major Players R&D Expenditure. 2023
2. 5.2 Company Profiles
  1. 5.2.1 Novartis (CH)
    1. 5.2.1.1 Financial Overview
    2. 5.2.1.2 Products Offered
    3. 5.2.1.3 Key Developments
    4. 5.2.1.4 SWOT Analysis
    5. 5.2.1.5 Key Strategies
  2. 5.2.2 Bristol-Myers Squibb (US)
    1. 5.2.2.1 Financial Overview
    2. 5.2.2.2 Products Offered
    3. 5.2.2.3 Key Developments
    4. 5.2.2.4 SWOT Analysis
    5. 5.2.2.5 Key Strategies
  3. 5.2.3 Amgen (US)
    1. 5.2.3.1 Financial Overview
    2. 5.2.3.2 Products Offered
    3. 5.2.3.3 Key Developments
    4. 5.2.3.4 SWOT Analysis
    5. 5.2.3.5 Key Strategies
  4. 5.2.4 Roche (CH)
    1. 5.2.4.1 Financial Overview
    2. 5.2.4.2 Products Offered
    3. 5.2.4.3 Key Developments
    4. 5.2.4.4 SWOT Analysis
    5. 5.2.4.5 Key Strategies
  5. 5.2.5 GSK (GB)
    1. 5.2.5.1 Financial Overview
    2. 5.2.5.2 Products Offered
    3. 5.2.5.3 Key Developments
    4. 5.2.5.4 SWOT Analysis
    5. 5.2.5.5 Key Strategies
  6. 5.2.6 Sanofi (FR)
    1. 5.2.6.1 Financial Overview
    2. 5.2.6.2 Products Offered
    3. 5.2.6.3 Key Developments
    4. 5.2.6.4 SWOT Analysis
    5. 5.2.6.5 Key Strategies
  7. 5.2.7 Pfizer (US)
    1. 5.2.7.1 Financial Overview
    2. 5.2.7.2 Products Offered
    3. 5.2.7.3 Key Developments
    4. 5.2.7.4 SWOT Analysis
    5. 5.2.7.5 Key Strategies
  8. 5.2.8 Merck & Co. (US)
    1. 5.2.8.1 Financial Overview
    2. 5.2.8.2 Products Offered
    3. 5.2.8.3 Key Developments
    4. 5.2.8.4 SWOT Analysis
    5. 5.2.8.5 Key Strategies
3. 5.3 Appendix
  1. 5.3.1 References
  2. 5.3.2 Related Reports
6 LIST OF FIGURES
1. 6.1 MARKET SYNOPSIS
2. 6.2 US MARKET ANALYSIS BY TYPE
3. 6.3 US MARKET ANALYSIS BY DIAGNOSIS
4. 6.4 US MARKET ANALYSIS BY TREATMENT
5. 6.5 US MARKET ANALYSIS BY END-USER
6. 6.6 KEY BUYING CRITERIA OF MEDICAL DEVICE
7. 6.7 RESEARCH PROCESS OF MRFR
8. 6.8 DRO ANALYSIS OF MEDICAL DEVICE
9. 6.9 DRIVERS IMPACT ANALYSIS: MEDICAL DEVICE
10. 6.10 RESTRAINTS IMPACT ANALYSIS: MEDICAL DEVICE
11. 6.11 SUPPLY / VALUE CHAIN: MEDICAL DEVICE
12. 6.12 MEDICAL DEVICE, BY TYPE, 2024 (% SHARE)
13. 6.13 MEDICAL DEVICE, BY TYPE, 2024 TO 2035 (USD Million)
14. 6.14 MEDICAL DEVICE, BY DIAGNOSIS, 2024 (% SHARE)
15. 6.15 MEDICAL DEVICE, BY DIAGNOSIS, 2024 TO 2035 (USD Million)
16. 6.16 MEDICAL DEVICE, BY TREATMENT, 2024 (% SHARE)
17. 6.17 MEDICAL DEVICE, BY TREATMENT, 2024 TO 2035 (USD Million)
18. 6.18 MEDICAL DEVICE, BY END-USER, 2024 (% SHARE)
19. 6.19 MEDICAL DEVICE, BY END-USER, 2024 TO 2035 (USD Million)
20. 6.20 BENCHMARKING OF MAJOR COMPETITORS
7 LIST OF TABLES
1. 7.1 LIST OF ASSUMPTIONS
7.1.1
1. 7.2 US MARKET SIZE ESTIMATES; FORECAST
  1. 7.2.1 BY TYPE, 2025-2035 (USD Million)
  2. 7.2.2 BY DIAGNOSIS, 2025-2035 (USD Million)
  3. 7.2.3 BY TREATMENT, 2025-2035 (USD Million)
  4. 7.2.4 BY END-USER, 2025-2035 (USD Million)
2. 7.3 PRODUCT LAUNCH/PRODUCT DEVELOPMENT/APPROVAL
7.3.1
1. 7.4 ACQUISITION/PARTNERSHIP
7.4.1

Certified Researchers

Customize Report

US Medical Device Market Segmentation

Medical Device By Type (USD Million, 2025-2035)

X-Linked Chronic Granulomatous Disease
Autosomal Recessive Chronic Granulomatous Disease

Medical Device By Diagnosis (USD Million, 2025-2035)

Neutrophil Function Tests
Genetic Testing
Prenatal Testing
Others

Medical Device By Treatment (USD Million, 2025-2035)

Infection Management
Interferon-gamma
Stem Cell Transplantation
Others

Medical Device By End-User (USD Million, 2025-2035)

Hospitals
Clinical Laboratories
Others

Customer Stories

“This is really good guys. Excellent work on a tight deadline. I will continue to use you going forward and recommend you to others. Nice job”

Noah Malgeri Co-Founder

“Thanks. It’s been a pleasure working with you, please use me as reference with any other Intel employees.”

Joseph Aguayo Sales Operations & Pricing Manager

“Thanks for sending the report it gives us a good global view of the Betaïne market.”

Peter Groot koerkamp Account and Business Manager

“Thank you, this will be very helpful for OQS.”

La Terria Dodd Program Support Specialist

“We found the report very insightful! we found your research firm very helpful. I'm sending this email to secure our future business.”

Younghwan Choi Senior Retail Manager

“I am very pleased with how market segments have been defined in a relevant way for my purposes (such as "Portable Freezers & refrigerators" and "last-mile"). In general the report is well structured. Thanks very much for your efforts.”

Mark Irwin Management Consultant

“I have been reading the first document or the study, ,the Global HVAC and FP market report 2021 till 2026. Must say, good info! I have not gone in depth at all parts, but got a good indication of the data inside!”